Johnson & Johnson News

Johnson & Johnson is a large and diverse company, so staying up-to-date with developments, company performance, and their plans for the future is not easy. That's why Wiser created the Johnson & Johnson news digest. It is delivered once a day and contains the key articles from around the web in order to keep you informed. Johnson & Johnson is primarily involved in the health sector. Its interests are spread across 275 different companies in 60 countries. It was founded in 1886 and its headquarters is in New Jersey. Worldwide it employs about 128,000 people and its main consumer brands include Band-Aid, Johnson's baby products and Neutrogena. It also has a medical devices and diagnostics sector, and a pharmaceuticals sector. Challenges exist in the later, particularly regarding the competition from generic versions of some of its drugs. Its research and development pipeline is also watched with interest, as is its movements in terms of expansion - further acquisitions, particularly in the medical devices field, are expected. Make sure you do not miss any Johnson & Johnson news, analysis or information by registering for the free Wiser daily email.

Recent Johnson & Johnson News Coverage
 
Your Weekly Recommendations Wednesday, July 26, 2017
 
Recommended for you
Samsung Releases Arthritis Drug in First Step Into U.S. Pharmaceuticals
The Wall Street Journal • Timothy W. Martin
Johnson & Johnson’s Pricey Best-Selling Drug Will Have to Face a 35% Cheaper Rival
Fortune Magazine • Sy Mukherjee
Johnson & Johnson Is A Defensive Stock And Should Be In All Portfolios, Income Or Growth
Seeking Alpha • William Stamm
Johnson & Johnson's Weakness Worries Me
Seeking Alpha • Josh Arnold
North American spinal implants market to hit $7B by 2024 — 3 observations
Becker's Spine Review • Megan Wood
Johnson & Johnson: This Market Will Buy Anything
Seeking Alpha • Stone Fox Capital
Johnson & Johnson's (JNJ) CEO Alex Gorsky on Q2 2017 Results - Earnings Call Transcript
Seeking Alpha
Johnson & Johnson Is Delivering
Seeking Alpha • Quad 7 Capital
Johnson & Johnson 2017 Q2 - Results - Earnings Call Slides
Seeking Alpha
Johnson & Johnson raises 2017 profit forecast; second-quarter earnings beat Street
Reuters
 
Recommended for You
Johnson & Johnson, Manufacturing
Samsung Releases Arthritis Drug in First Step Into U.S. Pharmaceuticals
The Wall Street JournalTimothy W. Martin
Americans suffering from arthritis can now find relief from an unexpected new player in the pharmaceuticals market. South Korea’s Samsung conglomerate, best known for its smartphones and televisions, will make available on Monday in the U.S. its lower-price copy of Johnson &...
Share
Biotechnology, Brand Management
Johnson & Johnson’s Pricey Best-Selling Drug Will Have to Face a 35% Cheaper Rival
Fortune MagazineSy Mukherjee
U.S. pharma giant Merck (mrk, -0.10%) and partner Samsung Bioepis are trying to take a big cut of Johnson & Johnson's (jnj, -1.70%) drug revenues. The companies have begun to market their "biosimilar" (a generic version of expensive biologic drugs) of Remicade—a...
Share
Health Finance, Johnson & Johnson
Johnson & Johnson Is A Defensive Stock And Should Be In All Portfolios, Income Or Growth
Seeking AlphaWilliam Stamm
Summary Johnson & Johnson Inc.'s total return over-performed the Dow for the 54.5-month test period by 38.01%. Johnson & Johnson's dividend is 2.5% and has been increased for 55 years, making it a Dividend King, and the dividend is well covered. Johnson...
Share
Actelion Pharmaceuticals, Johnson & Johnson
Johnson & Johnson's Weakness Worries Me
Seeking AlphaJosh Arnold
Summary JNJ reported Q2 earnings yesterday, and the stock is up. Investors are looking past revenue and margin weakness. But as the stock makes a move for another all-time high, the fundamentals just don't line up. When I previewed Johnson & Johnson...
Share
Economic Policy, Johnson & Johnson
North American spinal implants market to hit $7B by 2024 — 3 observations
Becker's Spine ReviewMegan Wood
The North American spinal implants market will reach $7 billion by 2024, based on a Data Bridge Market Research report, according to medGadget. Here are three observations: 1. In 2016, the market was valued at $4.7 billion. 2. The North American spinal...
Share
Health Finance, Johnson & Johnson
Johnson & Johnson: This Market Will Buy Anything
Seeking AlphaStone Fox Capital
Summary JNJ reported mixed Q2 results. Despite lackluster numbers, the stock trades near all-time highs. The dividend yield hit a decade low as capital returns plunge with the rising stock price. Before the open on Tuesday, Johnson & Johnson (JNJ) reported Q2...
Share
Actelion Pharmaceuticals, Health Finance
Johnson & Johnson's (JNJ) CEO Alex Gorsky on Q2 2017 Results - Earnings Call Transcript
Seeking Alpha
Johnson & Johnson (NYSE:JNJ) Q2 2017 Results Earnings Conference Call July 18, 2017, 08:30 AM ET Executives Joseph Wolk - VP, IR Alex Gorsky - Chairman & CEO Dominic Caruso - EVP & CFO Analysts Glenn Novarro - RBC Capital Markets Mike...
Share
Actelion Pharmaceuticals, Health Finance
Johnson & Johnson Is Delivering
Seeking AlphaQuad 7 Capital
Summary Earnings are out and key metrics are discussed. Currency issues are back. Actelion should ramp up second half sales. Johnson & Johnson (NYSE:JNJ) has just reported earnings which once again continue to impress here in 2017 which I have described as...
Share
Health Finance, Johnson & Johnson
Johnson & Johnson 2017 Q2 - Results - Earnings Call Slides
Seeking Alpha
The following slide deck was published by Johnson & Johnson in conjunction with their 2017 Q2 earnings call.
Share
Accounting, Johnson & Johnson
Johnson & Johnson raises 2017 profit forecast; second-quarter earnings beat Street
Reuters
() - Johnson & Johnson (JNJ.N) on Tuesday raised its full-year profit forecast and reported better-than-expected quarterly earnings, helped by strong demand for its newer products. The diversified healthcare company, which completed its $30 billion acquisition of Swiss biotech Actelion (ATLN.S) last...
Share